GLP-1 Drugs 'Work for Everyone' — A New Meta-Analysis Says That's Not the Whole Story

GLP-1 Drugs "Work for Everyone" — A New Meta-Analysis Says That's Not the Whole Story

Everyone is on Ozempic. Your neighbor lost 40 pounds. Your coworker lost 8. Same drug, same dose, wildly different results — and most of the coverage you've read just shrugs and moves on.

The popular narrative is that GLP-1 receptor agonists are a near-universal weight loss solution. The research tells a more complicated story. And a major 2026 systematic review published in JAMA Internal Medicine just put hard numbers on exactly how complicated it is.

Important: I'm not a doctor. Everything I share here is based on published research. Talk to your physician before making any changes to your health regimen.

---

The Bottom Line

• GLP-1 drugs like semaglutide and liraglutide produce very different results depending on who's taking them — age, sex, baseline weight, and diabetes status all appear to matter significantly.
• A 2026 systematic review and meta-analysis in JAMA Internal Medicine specifically examined this variability (called "heterogeneity of treatment effects") across multiple GLP-1 trials.
• People with diabetes, on average, lose less weight than people without diabetes on the same GLP-1 drugs — a counterintuitive finding that challenges how these medications are often marketed.
• Women and older adults may respond differently than men and younger patients — though the evidence here is still developing.
• Actionable takeaway: Before starting a GLP-1 protocol, ask your doctor how your specific profile (age, sex, diabetes status, baseline BMI) maps to the subgroups that showed the strongest — or weakest — responses in trials.

---

The Popular Belief: GLP-1 Drugs Are a Rising Tide That Lifts All Boats

When Wegovy and Ozempic broke into public consciousness, the headlines all sang the same tune. "Revolutionary weight loss drug." "Works for most people." "Up to 15% body weight reduction."

Those numbers are real. The STEP trials for semaglutide showed average weight loss of around 15% of body weight over 68 weeks. That is genuinely impressive. The SURMOUNT trials for tirzepatide pushed that even higher — closer to 20-22% in some groups.

But "average" is doing a lot of heavy lifting in those sentences.

When a drug works 22% for some people and 4% for others, the average of 13% sounds great on a press release. It tells you almost nothing about whether you will be one of the 22% or the 4%.

---

What the 2026 Meta-Analysis Actually Found

The Alexander et al. systematic review, published in JAMA Internal Medicine in May 2026, set out to answer a specific question: Does the effectiveness of GLP-1 receptor agonists for weight loss actually vary based on who is taking them?

The short answer: yes, meaningfully.

The researchers pooled data across multiple randomized controlled trials of GLP-1 drugs. They specifically looked at whether outcomes differed by age, sex, baseline BMI, diabetes status, and other characteristics.

Here is what stood out.

People without diabetes lost more weight. This one surprised a lot of clinicians. GLP-1 drugs were originally developed as diabetes medications. But the data suggests that people who are obese without type 2 diabetes may actually see stronger weight loss responses. People with diabetes appear to get meaningful metabolic benefits, but the scale doesn't move as far on average.

Sex differences showed up in the data. The evidence here is still being worked out, but the review found signals suggesting men and women may not respond identically. A separate 2026 study published in The Journal of Arthroplasty found that women on GLP-1 weight loss therapy faced different complication profiles than men in surgical contexts — hinting that biological sex interacts with these drugs in ways we're only beginning to map.

Baseline characteristics matter more than most patients are told. Where you start — your initial BMI, your metabolic health, your age — appears to shift your likely outcome meaningfully. The drug is not equally powerful across all starting lines.

---

Why This Challenges the "It Works" Consensus

The consensus isn't wrong, exactly. GLP-1 drugs do work — supported by substantial published research. The problem is the framing.

When a drug shows 70% of trial participants losing at least 5% of body weight, that sounds like a near-universal win. But it also means roughly 30% didn't hit that bar. And it says nothing about who fell into which group, or why.

This matters for two reasons.

First, it affects expectations. Someone who matches the demographic profile of a low-responder subgroup may be set up for disappointment — or worse, may blame themselves for a biological reality that was somewhat predictable from the start.

Second, it affects clinical decision-making. If certain patients are much more likely to respond strongly, and others are likely to see modest effects, that changes the risk-benefit calculation. A drug with real side effects (nausea, vomiting, potential muscle loss — more on that below) deserves a more personalized cost-benefit analysis than "it works on average."

---

The Side Effects Don't Hit Everyone Equally Either

Here's another layer the "GLP-1 works" narrative tends to flatten: the downside profile is also variable.

A 2026 population-based observational study raised concerns about muscle atrophy associated with GLP-1 receptor agonist use. Muscle loss during rapid weight reduction is a known risk across any weight loss intervention — but the scale of weight loss these drugs produce makes it a more pressing concern. Not everyone loses the same proportion of muscle mass, and factors like protein intake, resistance training, and baseline muscle mass all appear to moderate that risk.

There's also emerging data on hair loss. Research published in 2026 flagged GLP-1-associated hair loss as a growing clinical concern — a side effect that affects some users significantly and others not at all, and is likely tied to the rate and magnitude of weight loss rather than the drug itself.

Even cardiac benefits — one of the most celebrated effects of these drugs — don't play out uniformly. A 2026 review in Circulation: Heart Failure examined how GLP-1 drugs help in heart failure with preserved ejection fraction (HFpEF), finding that some of the benefit appears to be weight-loss-dependent and some appears to be independent of weight loss entirely. That distinction matters — it means the drug may work through different mechanisms in different patients.

---

So Who *Does* Respond Best to GLP-1s for Weight Loss?

Based on the current evidence, the profile of a likely strong responder looks something like this:

• No type 2 diabetes — or well-controlled blood sugar, rather than highly dysregulated glucose metabolism
• Higher baseline BMI — more weight to lose generally correlates with larger absolute and relative responses
• Consistent use and dose escalation — adherence to the titration schedule matters; more side effects often mean slower titration, which affects outcomes
• Combined with lifestyle modification — trials showing the biggest effects almost always included dietary and exercise support alongside the drug

This is not a perfect predictive formula. But it is a more honest starting point than "it works."

---

The Bigger Picture: Average Isn't You

Here is the thing about averages in medicine. They are useful for regulatory approval. They are useful for population-level policy. They are not useful for you, specifically, sitting across from your doctor trying to decide whether a weekly injection is worth it.

The field is slowly moving toward more personalized prescribing. Researchers are actively trying to identify biomarkers that predict who will respond strongly to GLP-1 drugs — genetic factors, gut microbiome composition, baseline hormonal profiles. That work is not done yet.

In the meantime, the best you can do is go into the conversation informed. Know that the headline number — 15% average weight loss — is a population average, not a personal forecast. Know that your age, sex, diabetes status, and baseline health appear to shape your likely response. Know that the side effects are also variable, and that "generally well-tolerated in studies" does not mean side-effect-free for every individual.

The drug is real. The results are real. The variance is also real — and it deserves the same airtime.

---

FAQ

Does semaglutide work the same for men and women? The evidence suggests there may be differences, though the data is still developing. A 2026 systematic review found signals of sex-based variability in GLP-1 treatment effects. Some research also suggests women may face different risk profiles in surgical contexts following GLP-1 weight loss therapy. Talk to your doctor about how your individual profile maps to the trial data.

Why do some people lose almost no weight on Ozempic? Several factors appear to influence response: diabetes status (people with type 2 diabetes may lose less weight on average), baseline BMI, how closely the drug is combined with dietary changes, and individual biological factors not yet fully understood. The 2026 meta-analysis in JAMA Internal Medicine confirmed that treatment effects are meaningfully heterogeneous across the population.

Do GLP-1 drugs cause muscle loss? A 2026 observational study raised concerns about muscle atrophy associated with GLP-1 use. Significant weight loss from any cause can reduce muscle mass. Strategies like resistance training and adequate protein intake are generally recommended alongside GLP-1 therapy to help preserve muscle. Discuss this with your healthcare provider before starting treatment.

Is tirzepatide better than semaglutide for weight loss? On average, tirzepatide (a dual GLP-1/GIP agonist) has shown larger weight loss in clinical trials. But the same principle applies: averages mask individual variation. Whether one is better for you specifically depends on factors your doctor can help assess.

Who is most likely to respond well to GLP-1 drugs for weight loss? Based on current research, people without type 2 diabetes, with higher baseline BMI, and who combine the medication with dietary and lifestyle modifications tend to show stronger weight loss responses. But this is an active area of research, and individual results genuinely vary.

---

The Takeaway: Ask Better Questions Before You Start

GLP-1 receptor agonists are among the most significant advances in metabolic medicine in decades. That is not in dispute.

What the 2026 meta-analysis adds to that story is nuance — the kind of nuance that makes a real difference when you're making a personal medical decision.

Before starting any GLP-1 protocol, the most useful question isn't "does this drug work?" It's "does this drug work for someone like me, given my specific health profile?"

Your doctor may not have a perfect answer. But they should have a more specific answer than "yes, it works." Push for that specificity. You've earned it.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research — not medical recommendations.

---

Sources

1. Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis — JAMA Internal Medicine, 2026
2. Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit — Circulation: Heart Failure, 2026
3. GLP-1 Receptor Agonist Weight Loss Therapy and Arthroplasty: Are Women at Greater Risk for Complications? — The Journal of Arthroplasty, 2026
4. Muscle Atrophy Associated with Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Observational Study — 2026
5. Glucagon-like Peptide-1 Receptor Agonists and Hair Loss: An Emerging Clinical Concern — 2026
6. GLP-1/GIP Dual Agonist Tirzepatide in Obstructive Sleep Apnea Syndrome: Mechanisms, Evidence, and Clinical Perspectives — Frontiers in Medicine, 2026